Triple inhalers for obstructive airways disease: Will they be useful?

Expert Review of Respiratory Medicine

Volumn 5, Issue 3, 2011, Pages 297-300

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

asthma; COPD; corticosteroid; indacaterol; long acting muscarinic antagonist; tiotropium

Indexed keywords

ACLIDINIUM BROMIDE; ACLIDINIUM BROMIDE PLUS FORMOTEROL; ALMIRALL; BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CICLESONIDE PLUS FORMOTEROL PLUS TIOTROPIUM BROMIDE; CORTICOSTEROID; FLUTICASONE FUROATE; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; GSK 573719; GSK 573719 PLUS VILANTEROL; GSK 961081; INDACATEROL; INDACATEROL PLUS MOMETASONE FUROATE; MOMETASONE FUROATE; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; QVA 149; RELOVAIR; SALMETEROL; TIOTROPIUM BROMIDE; TRIOHALE; UNCLASSIFIED DRUG; VILANTEROL;

ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENTIATION; FORCED EXPIRATORY VOLUME; HUMAN; REVIEW; TREATMENT OUTCOME;

EID: 79959732794     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.26     Document Type: Review

References (40)

1. Nannini L, Cates C, Lasserson T et al. Combined corticosteroid and long-acting β-agonist in one inhaler versus long-acting β-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 4, CD006829 (2007
2. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775-789 (2007 (Pubitemid 46294610)
3. Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 21, 74-81 (2003 (Pubitemid 36150304)
4. Calverley PM, Kuna P, Monso E et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir. Med. 104, 1858-1868 (2010
5. Yang IA, Fong KM, Sim EH et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2, CD002991 (2007
6. Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration 80, 89-95 (2010
7. Suissa S, Ernst P, Vandemheen KL et al. Methodological issues in therapeutic trials of COPD. Eur. Respir. J. 31, 927-933 (2008
8. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J. 34, 13-16 (2009
9. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of COPD - 2006 Update. Am. J. Respir. Crit. Care Med. 176, 532-555 (2007
10. Drummond MB, Dasenbrook EC, Pitz MW et al. Inhaled corticosteroids in patients with stable chronic obstructivepulmonary disease: a systematic review and meta-analysis. JAMA 300, 2407-2416 (2008
11. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 123, 1001-1006 (2010
12. Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 5, 189-195 (2010
13. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 1543-1554 (2008
14. Decramer M, Celli B, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 374, 1171-1178 (2009
15. Wedzicha JA, Calverley PM, Seemungal TA et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 177, 19-26 (2008
16. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting b2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 3, CD007891 (2010
17. Singh D, Brooks J, Hagan G et al. Superiority of 'triple' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63, 592-598 (2008 (Pubitemid 351969251)
18. Cazzola M, Ando F, Santus P et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm. Pharmacol. Ther. 20, 556-561 (2007 (Pubitemid 47077647)
19. Aaron SD, Vandemheen KL, Fergusson D et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 146, 545-555 (2007 (Pubitemid 351650535)
20. Karner C, Cates CJ. Combination inhaled steroid and long-acting b(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 3, CD008532 (2011
21. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 34, 757-769 (2009
22. Korn S, Kerwin E, Atis S et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir. Med. 105(5), 719-726 (2011
23. Barnes PJ, Pocock SJ, Magnussen H et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm. Pharmacol. Ther. 23, 165-171 (2010
24. Vogelmeier C, Ramos-Barbon D, Jack D et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir. Res. 11, 135 (2010
25. Chapman KR, Rennard SI, Dogra A et al. Long-term Safety and Efficacy of Indacaterol, a Novel Long-acting {b}2- Agonist, in Subjects with COPD: a Randomized, Placebo-controlled Study. Chest DOI: 10.1378/chest.10-1830 (2011) (Epub ahead of print
26. van Noord JA, Aumann JL, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129, 509-517 (2006
27. van Noord JA, Aumann JL, Janssens E et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir. Med. 104, 995-1004 (2010
28. Tashkin DP, Pearle J, Iezzoni D et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 6, 17-25 (2009
29. Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr. Opin. Investig. Drugs 10, 482-490 (2009
30. Gibson PG, Powell H, Ducharme FM. Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J. Allergy Clin. Immunol. 119, 344-350 (2007 (Pubitemid 46206143)
31. Ducharme FM, Ni CM, Greenstone I et al. Addition of long-acting b2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst. Rev. 5, CD005535 (2010
32. Edwards SJ, von Maltzahn R, Naya IP et al. Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. Int. J. Clin. Pract. 64, 619-627 (2010
33. Magnussen H, Bugnas B, van Noord J et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir. Med. 102, 50-56 (2008 (Pubitemid 350151827)
34. Park HW, Yang MS, Park CS et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 64, 778-783 (2009
35. Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364, 1505-1512 (2004 (Pubitemid 39410416)
36. Peters SP, Kunselman SJ, Icitovic N et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med. 363, 1715-1726 (2010
37. Lavorini F, Magnan A, Christophe DJ et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med. 102, 593-604 (2007
38. Pitchayajittipong C, Shur J, Price R. Engineering of crystalline combination inhalation particles of a long-acting b2-agonist and a corticosteroid. Pharm. Res. 26, 2657-2666 (2009
39. Ray NC, Alcaraz L. Muscarinic antagonist-β-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review. Expert Opin. Ther. Pat. 19, 1-12 (2009
40. Barnes PJ. Emerging pharmacotherapies for COPD. Chest 134, 1278-1286 (2008).